ERBB2 and breast carcinoma: Combined with the result from first two steps, we have identified 8 compounds that selectively inhibited HER2-positive breast cancer cell proliferation by more than 50% at 10 μmol/L after a 72-hour incubation (step 1) compare to no anti-proliferation activity against HER2-negative breast cancer cells (step 2).